** Shares of Edgewise Therapeutics rise about 17% to $32.28 in premarket trading
** Company says its experimental genetic disorder drug met the main goal in a mid-stage study
** The drug, sevasemten, is being developed to treat Becker Muscular Dystrophy, a rare condition that results in progressive muscle weakness and degeneration
** Sevasemten helped significantly reduce levels of creatine kinase, an enzyme associated with skeletal muscle damage in the study- EWTX
** Up to last close, stock more than doubled YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.